The webinar will feature presentations from Key Opinion Leaders, Stuart Goldstein, MD, from Cincinnati Children’s Hospital, and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center, who will discuss the unmet medical need for anticoagulation of the extracorporeal circuit, the most commonly known being dialysis machines. Currently, there are no FDA-approved regional anticoagulants for use in the extracorporeal circuit. AcelRx’s product candidate, Niyad™, a lyophilized form of nafamostat is in development as a regional anticoagulant for injection into the extracorporeal circuit to prevent clotting and ensure effective treatment is provided to the patient. Niyad is being regulated as a device by the FDA and has been approved and used in Japan and Korea for several decades. In the U.S., the Food and Drug Administration has granted Niyad Breakthrough Device Designation status.

Nafamostat is a broad-spectrum synthetic serine protease inhibitor with anticoagulant, anti-inflammatory, and anti-viral activities. LTX-608 (intravenous nafamostat) is in potential development by AcelRx for multiple indications – including disseminated intravascular coagulation (DIC), anti-viral treatment for COVID-19 and other disease states.

A live question and answer session will follow.